SynBiotic SE Launches its Own Medical Cannabis Brand: Hempamed Rx

In mid-September, the pharmacy market will be attending Expopharm, the most important leading European trade fair. SynBiotic SE will present its new brand Hempamed Rx at its own booth. Europe’s largest group of companies in the hemp and cannabis sector is launching an extensive range of full-spectrum extracts, dronabinol, and other diverse flowers.

In this process, canna.sales GmbH becomes SynBiotic Sales GmbH, with a fifteen-person field sales team consisting of employees with many years of experience in the field of medical cannabis, and GECA Pharma GmbH, responsible for the import and distribution of medical cannabis products, becoming SynBiotic Distribution GmbH.

Read more on the subject and find the latest cannabis news of the day with the Hemp.im mobile app.

Distribution increase in the field of medical cannabis

“While other cannabis companies are downsizing their sales teams and seemingly only eyeing the legalization of recreational use, we are keeping a firm eye on all areas of the existing and future cannabis market,” says Lars Müller, CEO of SynBiotic SE. “With Hempamed Rx, we are not only focusing on a new strong brand for medical cannabis, we are also further expanding our sales team under the SynBiotic Sales umbrella.” The goal: to provide competent advice throughout Germany.

With the sales offensive, the Munich-based group of companies wants to underline its clear vision in the wake of increasing treatments and prescriptions for medical cannabis. Products from this area can be used to treat chronic pain, among other things. In particular, patients suffering from depression and anxiety/sleep disorders, but also Tourette’s, MS or epilepsy, can alleviate their symptoms and the resulting pain by using medical cannabis.

Strong pipeline: Unprecedented product innovations

SynBiotic SE will continue to build capacity in the important area of medical cannabis and further expand its dominant position in the market, not only on the distribution side. The launch of Hempamed Rx also culminates years of research and development of innovative products that will be launched under the new brand in the coming weeks and months. Particularly in the field of medical cannabis, it is important to enable treatments that are optimally adapted to individual complaints. The dosage forms in particular make an important contribution to this. In order to enable everyone to benefit from the advantages of medical cannabis, SynBiotic SE is constantly expanding its product portfolio through the use of various carrier substances. The high bio-availability is as much in focus as the good tolerability of the products.

Visitors to Expopharm in Munich can find out all about the new Hempamed Rx brand, SynBiotic Sales GmbH and SynBiotic Distribution GmbH from 14 to 17 September 2022 in Hall B1 at Stand C58.

__

(Featured image by Terrance Barksdale via Pexels)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in finanzen.net, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.